hydroxychloroquine has been researched along with Cardiovascular Stroke in 17 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction." | 9.41 | Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. ( Anttila, I; Anttonen, O; Drews, T; Eklund, KK; Hartman, O; Karjalainen, P; Koskinen, M; Kovanen, PT; Kuusisto, J; Lehtonen, J; Nieminen, T; Nurmi, K; Paakkanen, R; Rissanen, TT; Ryysy, R; Silventoinen, K; Sinisalo, J; Tolppanen, H; Ulander, L; Utriainen, S; Yrjölä, J, 2021) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 8.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Hydroxychloroquine is often used as a first-line treatment of rheumatoid arthritis despite limited evidence on its cardiovascular risk." | 8.12 | Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. ( D'Andrea, E; Desai, RJ; Glynn, RJ; He, M; Kim, SC; Lee, H; Weinblatt, ME, 2022) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 8.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 6.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| "To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction." | 5.41 | Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. ( Anttila, I; Anttonen, O; Drews, T; Eklund, KK; Hartman, O; Karjalainen, P; Koskinen, M; Kovanen, PT; Kuusisto, J; Lehtonen, J; Nieminen, T; Nurmi, K; Paakkanen, R; Rissanen, TT; Ryysy, R; Silventoinen, K; Sinisalo, J; Tolppanen, H; Ulander, L; Utriainen, S; Yrjölä, J, 2021) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 4.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Hydroxychloroquine is often used as a first-line treatment of rheumatoid arthritis despite limited evidence on its cardiovascular risk." | 4.12 | Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. ( D'Andrea, E; Desai, RJ; Glynn, RJ; He, M; Kim, SC; Lee, H; Weinblatt, ME, 2022) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 4.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| "Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation." | 3.01 | Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19? ( Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 2.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | 2.72 | Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 9 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Jorge, A | 1 |
| Lu, N | 1 |
| Choi, H | 1 |
| Esdaile, JM | 1 |
| Lacaille, D | 1 |
| Avina-Zubieta, JA | 1 |
| D'Andrea, E | 1 |
| Desai, RJ | 1 |
| He, M | 1 |
| Glynn, RJ | 1 |
| Lee, H | 1 |
| Weinblatt, ME | 1 |
| Kim, SC | 1 |
| Kukreja, RC | 1 |
| Wang, R | 1 |
| Koka, S | 1 |
| Das, A | 1 |
| Samidurai, A | 1 |
| Xi, L | 1 |
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 1 |
| Masoumi, A | 1 |
| Jacquet-Lagrèze, M | 1 |
| Riad, Z | 1 |
| Hugon-Vallet, E | 1 |
| Ferraris, A | 1 |
| Fellahi, JL | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Petri, M | 1 |
| Konig, MF | 1 |
| Li, J | 1 |
| Goldman, DW | 1 |
| Chen, J | 1 |
| Norling, LV | 1 |
| Cooper, D | 1 |
| Ulander, L | 1 |
| Tolppanen, H | 1 |
| Hartman, O | 2 |
| Rissanen, TT | 1 |
| Paakkanen, R | 1 |
| Kuusisto, J | 1 |
| Anttonen, O | 1 |
| Nieminen, T | 1 |
| Yrjölä, J | 1 |
| Ryysy, R | 1 |
| Drews, T | 1 |
| Utriainen, S | 1 |
| Karjalainen, P | 1 |
| Anttila, I | 1 |
| Nurmi, K | 1 |
| Silventoinen, K | 1 |
| Koskinen, M | 1 |
| Kovanen, PT | 2 |
| Lehtonen, J | 2 |
| Eklund, KK | 2 |
| Sinisalo, J | 2 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 1 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| Zhang, Y | 1 |
| Zhang, L | 1 |
| Wang, X | 1 |
| Zheng, L | 1 |
| Lv, J | 1 |
| Zhang, W | 1 |
| Zhao, H | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Gallus, AS | 1 |
| Hirsh, J | 2 |
| Gent, M | 1 |
| Genton, E | 1 |
| Krug, H | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial[NCT02648464] | Phase 4 | 125 participants (Actual) | Interventional | 2016-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for hydroxychloroquine and Cardiovascular Stroke
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2023 |
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
Left ventricular dysfunction in COVID-19: A diagnostic issue.
Topics: Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytokine Release Syndro | 2020 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheuma | 2021 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
[Principles of anticoagulant therapy in myocardial infarct].
Topics: Acute Disease; Anticoagulants; Drug Interactions; Female; Fibrinolytic Agents; Humans; Hydroxychloro | 1972 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
3 trials available for hydroxychloroquine and Cardiovascular Stroke
| Article | Year |
|---|---|
Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.
Topics: Double-Blind Method; Humans; Hydroxychloroquine; Interleukin-6; Myocardial Infarction; Pilot Project | 2021 |
Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Topics: Antirheumatic Agents; Atherosclerosis; Double-Blind Method; Humans; Hydroxychloroquine; Myocardial I | 2017 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
7 other studies available for hydroxychloroquine and Cardiovascular Stroke
| Article | Year |
|---|---|
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Case-Control Studies; Humans; Hydroxy | 2023 |
Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Facto | 2022 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Chromatography, Liquid; Female; Fingers; Gangrene; Humans; Hydroxychlor | 2021 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Acute myocardial infarction in a young woman with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Coronary Angiography; Creatine K | 2015 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |